{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:11:13Z","timestamp":1775059873247,"version":"3.50.1"},"reference-count":88,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T00:00:00Z","timestamp":1507075200000},"content-version":"vor","delay-in-days":368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.jacc.2016.06.060","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T14:41:38Z","timestamp":1474987298000},"page":"1575-1589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["Hyperkalemia in Heart Failure"],"prefix":"10.1016","volume":"68","author":[{"given":"Chaudhry M.S.","family":"Sarwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lampros","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ileana","family":"Pi\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihai","family":"Gheorghiade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2016.06.060_bib1","doi-asserted-by":"crossref","first-page":"R225","DOI":"10.1186\/cc11872","article-title":"Severe hyperkalemia requiring hospitalization: predictors of mortality","volume":"16","author":"An","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.jacc.2016.06.060_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5114\/aoms.2014.42577","article-title":"Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes","volume":"10","author":"Khanagavi","year":"2014","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jacc.2016.06.060_bib3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1001\/archinte.158.8.917","article-title":"Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines","volume":"158","author":"Acker","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib4","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.amjcard.2012.01.367","article-title":"Predictors of hyperkalemia and death in patients with cardiac and renal disease","volume":"109","author":"Jain","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2016.06.060_bib5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2016.06.060_bib6","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.06.060_bib7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.amjcard.2014.12.045","article-title":"Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial)","volume":"115","author":"Khan","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2016.06.060_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates\u00a0of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib9","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ki.1990.295","article-title":"Early and late adjustment to potassium loading in humans","volume":"38","author":"Rabelink","year":"1990","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2016.06.060_bib10","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMra1313341","article-title":"An integrated view of potassium homeostasis","volume":"373","author":"Gumz","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/0003-4819-150-9-200905050-00008","article-title":"Narrative review: evolving concepts in potassium homeostasis and hypokalemia","volume":"150","author":"Greenlee","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib13","first-page":"E328","article-title":"Multiplicative interaction between angiotensin II and K concentration in stimulation of aldosterone","volume":"247","author":"Young","year":"1984","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jacc.2016.06.060_bib14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1210\/endo-125-1-486","article-title":"Production of renin, angiotensin II, and aldosterone by adrenal explant cultures: response to potassium and converting enzyme inhibition","volume":"125","author":"Shier","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/j.jacc.2016.06.060_bib15","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1210\/endo-125-5-2463","article-title":"Evidence that angiotensin-II and potassium collaborate to increase cytosolic calcium and stimulate the secretion of aldosterone","volume":"125","author":"Pratt","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/j.jacc.2016.06.060_bib16","doi-asserted-by":"crossref","first-page":"R1166","DOI":"10.1152\/ajpregu.00495.2012","article-title":"Role of pituitary in K+ homeostasis: impaired renal responses to altered K+ intake in hypophysectomized rats","volume":"304","author":"Oh","year":"2013","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jacc.2016.06.060_bib17","doi-asserted-by":"crossref","first-page":"R421","DOI":"10.1152\/ajpregu.00095.2011","article-title":"Gut sensing of dietary K+ intake increases renal K+ excretion","volume":"301","author":"Oh","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jacc.2016.06.060_bib18","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/ki.2015.243","article-title":"Evidence for a gastrointestinal-renal kaliuretic signaling axis in humans","volume":"88","author":"Preston","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2016.06.060_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2016.06.060_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40256-015-0130-7","article-title":"Potential new agents for the management of hyperkalemia","volume":"16","author":"Packham","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacc.2016.06.060_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ejhf.444","article-title":"Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease","volume":"18","author":"Bramlage","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2016.06.060_bib22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.mayocp.2013.06.005","article-title":"Role of dietary salt and potassium intake in cardiovascular health and disease: a review of the evidence","volume":"88","author":"Aaron","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2016.06.060_bib23","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib24","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.06.060_bib25","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.jacc.2013.05.020","article-title":"2013 ACCF\/AHA guideline for the management of heart\u00a0failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.06.060_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.06.060_bib27","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib28","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.06.060_bib29","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000013599","article-title":"Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors","volume":"20","author":"Ahuja","year":"2000","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jacc.2016.06.060_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib32","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ejhf.226","article-title":"Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice","volume":"17","author":"Michel","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2016.06.060_bib34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","article-title":"Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist","volume":"7","author":"Vardeny","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2016.06.060_bib35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ahj.2004.08.005","article-title":"Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"149","author":"Adams","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2016.06.060_bib36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.01730215","article-title":"Association between serum potassium and outcomes in patients with reduced kidney function","volume":"11","author":"Luo","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2016.06.060_bib37","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCHEARTFAILURE.113.000981","article-title":"Response to Sexton: Inhibiting the renin-angiotensin-aldosterone system in patients with heart failure and renal dysfunction: common sense or nonsense?","volume":"7","author":"Butler","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2016.06.060_bib38","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.06.060_bib39","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.06.060_bib40","unstructured":"HCUP Databases. Healthcare Cost and Utilization Project (HCUP). 2011. Rockville, MD: Agency for Healthcare Research and Quality. Available at: http:\/\/www.hcup-us.ahrq.gov\/databases.jsp. Accessed July 20,\u00a02016."},{"key":"10.1016\/j.jacc.2016.06.060_bib41","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1097\/CCM.0b013e31818f222b","article-title":"Management of severe hyperkalemia","volume":"36","author":"Weisberg","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib42","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1097\/01.ASN.0000100145.27188.33","article-title":"Management of glomerular proteinuria: a commentary","volume":"14","author":"Wilmer","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2016.06.060_bib43","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1681\/ASN.2010010079","article-title":"Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?","volume":"21","author":"Sterns","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2016.06.060_bib44","first-page":"315","article-title":"Heart failure and electrolyte disturbances","volume":"14","author":"Schwinger","year":"1992","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.jacc.2016.06.060_bib45","doi-asserted-by":"crossref","first-page":"28E","DOI":"10.1016\/0002-9149(90)90249-Z","article-title":"Interrelation of electrolytes and renin-angiotensin system in congestive heart failure","volume":"65","author":"Dargie","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2016.06.060_bib46","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2169\/internalmedicine.46.6415","article-title":"Analysis of factors causing hyperkalemia","volume":"46","author":"Takaichi","year":"2007","journal-title":"Intern Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib47","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"Lazich","year":"2014","journal-title":"Sem Nephrol"},{"key":"10.1016\/j.jacc.2016.06.060_bib48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/jhm.834","article-title":"The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia","volume":"6","author":"Kessler","year":"2011","journal-title":"J\u00a0Hosp Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib49","doi-asserted-by":"crossref","first-page":"264.e9","DOI":"10.1016\/j.amjmed.2012.08.016","article-title":"Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review","volume":"126","author":"Harel","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib50","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.amjmed.2013.02.034","article-title":"Incidence of sodium polystyrene sulfonate-associated colonic necrosis","volume":"126","author":"Yuan","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/IJNRD.S13871","article-title":"Hypernatremia in a patient treated with sodium polystyrene sulfonate","volume":"3","author":"Nepal","year":"2010","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.jacc.2016.06.060_bib52","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/j.ajkd.2012.04.023","article-title":"Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study","volume":"60","author":"Watson","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2016.06.060_bib53","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2215\/CJN.03640415","article-title":"Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD","volume":"10","author":"Lepage","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2016.06.060_bib54","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.06.060_bib55","first-page":"1","article-title":"Hyperkalemia in heart failure patients: current challenges and future prospects","volume":"2016","author":"L\u00f3pez-Vilella","year":"2016","journal-title":"Res Rep Clin Cardiol"},{"key":"10.1016\/j.jacc.2016.06.060_bib56","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2016.06.060_bib57","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1074248416629549","article-title":"Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia","volume":"21","author":"Li","year":"2016","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jacc.2016.06.060_bib58","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF02233563","article-title":"Ionic constituents and osmolality of gastric and small-intestinal fluids after eating","volume":"11","author":"Fordtran","year":"1966","journal-title":"Am J Digestive Diseases"},{"key":"10.1016\/j.jacc.2016.06.060_bib59","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00424-009-0781-9","article-title":"Colonic potassium handling","volume":"459","author":"Sorensen","year":"2010","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.jacc.2016.06.060_bib60","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2016.06.060_bib62","unstructured":"Fulton TB. Diffusion and transport across cell membranes [lecture]. Available at: http:\/\/biochemistry2.ucsf.edu\/programs\/ptf\/prologue%20links\/Diff%20&%20Trans%20Membranes.pdf. Accessed July 21,\u00a02016."},{"key":"10.1016\/j.jacc.2016.06.060_bib63","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2016.06.060_bib64","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1161\/CIRCHEARTFAILURE.109.899526","article-title":"Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies","volume":"3","author":"Bowling","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2016.06.060_bib65","unstructured":"Center for Drug Evaluation and Research. Application number: 205739Orig1s000. Risk Assessment and Risk Mitigation Review(s). Department of Health and Human Services, Public Health Service, Food and Drug Administration. 2015. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/205739Orig1s000RiskR.pdf. Accessed July 20,\u00a02016."},{"key":"10.1016\/j.jacc.2016.06.060_bib66","unstructured":"Relypsa Announces Results From Veltassa Drug-Drug Interaction Studies in Healthy Volunteers. Redwood City, CA: Relypsa, Inc.; 2016. Available at: http:\/\/investor.relypsa.com\/releasedetail.cfm?releaseid=951581. Accessed July 20,\u00a02016."},{"key":"10.1016\/j.jacc.2016.06.060_bib67","series-title":"Veltassa (patiromer) for oral suspension [prescribing information]","year":"2016"},{"key":"10.1016\/j.jacc.2016.06.060_bib68","doi-asserted-by":"crossref","first-page":"e114686","DOI":"10.1371\/journal.pone.0114686","article-title":"Characterization of structure and function of ZS-9, a K+ selective ion trap","volume":"9","author":"Stavros","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jacc.2016.06.060_bib69","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2016.06.060_bib70","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ki.2014.382","article-title":"A\u00a0phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient","volume":"88","author":"Ash","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2016.06.060_bib71","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.06.060_bib72","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0006-3495(96)79575-9","article-title":"Permeation of protons, potassium ions, and small polar molecules through phospholipid bilayers as a function of membrane thickness","volume":"70","author":"Paula","year":"1996","journal-title":"Biophys J"},{"key":"10.1016\/j.jacc.2016.06.060_bib73","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2016.06.060_bib74","first-page":"183","article-title":"Pathophysiology of heart failure and the renin-angiotensin-system","volume":"88","author":"Holtz","year":"1993","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jacc.2016.06.060_bib75","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11886-012-0258-x","article-title":"The role of renal denervation in the treatment of heart failure","volume":"14","author":"Sobotka","year":"2012","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacc.2016.06.060_bib76","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10741-015-9482-y","article-title":"Acid-base and electrolyte abnormalities in heart failure: pathophysiology and implications","volume":"20","author":"Urso","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacc.2016.06.060_bib77","doi-asserted-by":"crossref","first-page":"AP602","DOI":"10.1161\/hyp.66.suppl_1.p602","article-title":"Abstract P602: Patiromer decreased aldosterone, urine albumin\/creatinine ratio, and blood pressure in patients with chronic kidney disease and hyperkalemia on RAAS inhibitors: results from OPAL-HK [abstract]","volume":"66","author":"Weir","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2016.06.060_bib78","unstructured":"Epstein M, Mayo M, Garza D, et\u00a0al. Strategy for improved blood pressure (BP) control in resistant hypertension (RH) with diabetic kidney disease (DKD). Paper presented at: National Kidney Foundation Meeting; May 1, 2016; Boston, MA."},{"key":"10.1016\/j.jacc.2016.06.060_bib79","unstructured":"Tumlin, JA, Kosiborod M, Pergola PE, et\u00a0al. SA-PO1101: Long-term (52-week) efficacy and safety of ZS-9 in the treatment of hyperkalemia: interim\u00a0results from a phase 3 open-label, multi-center, multi-dose maintenance study. Paper presented at: Kidney Week; November 7, 2015; San Diego, CA."},{"key":"10.1016\/j.jacc.2016.06.060_bib80","unstructured":"Relypsa, Inc. Patiromer With or Without Food for the Treatment of Hyperkalemia (TOURMALINE). 2016. ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02694744. Accessed July 20,\u00a02016."},{"key":"10.1016\/j.jacc.2016.06.060_bib81","unstructured":"ZS Pharma, Inc. Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months. 2016. ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02163499. Accessed July 20,\u00a02016."},{"key":"10.1016\/j.jacc.2016.06.060_bib82","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00392-014-0678-2","article-title":"Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF","volume":"103","author":"Tebbe","year":"2014","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacc.2016.06.060_bib83","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from\u00a012,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2016.06.060_bib84","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13012-014-0169-x","article-title":"Leveraging practice-based research networks to accelerate implementation and diffusion of chronic kidney\u00a0disease guidelines in primary care practices: a prospective cohort study","volume":"9","author":"Mold","year":"2014","journal-title":"Implement Sci"},{"key":"10.1016\/j.jacc.2016.06.060_bib85","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0022-0736(75)80028-8","article-title":"Complete heart block with normal QRS duration occurring distal to the His bundle in acute inferior myocardial infarction","volume":"8","author":"Bashour","year":"1975","journal-title":"J\u00a0Electrocardiol"},{"key":"10.1016\/j.jacc.2016.06.060_bib86","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2215\/CJN.03700410","article-title":"Damned if you do, damned if you don't: potassium binding resins in hyperkalemia","volume":"5","author":"Watson","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2016.06.060_bib87","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5414\/CN108334","article-title":"Sodium polystyrene sulfonate\u2014is it truly effective treatment for hyperkalemia?","volume":"83","author":"Einbinder","year":"2015","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jacc.2016.06.060_bib88","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0272-6386(96)90460-6","article-title":"Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol","volume":"28","author":"Allon","year":"1996","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109716346563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109716346563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T06:47:28Z","timestamp":1656744448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109716346563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":88,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0735109716346563"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2016.06.060","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperkalemia in Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2016.06.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}